Last reviewed · How we verify
Unpulsed DCs
Unpulsed DCs are being investigated in multiple Phase 2 and Phase 1 trials for the treatment of glioblastoma multiforme (GBM). These dendritic cell therapies aim to enhance immune responses and deplete regulatory T cells (TRegs) to improve patient outcomes. Despite no FDA approval, ongoing and completed trials show promise in this novel immunotherapy approach.
At a glance
| Generic name | Unpulsed DCs |
|---|---|
| Also known as | Unpulsed DCs pre-conditioning |
| Sponsor | Mustafa Khasraw, MBChB, MD, FRCP, FRACP |
| Modality | Biologic |
| Phase | Phase 2 |